Oryzon Genomics S.A. Logo

Oryzon Genomics S.A.

ORY | MC

Overview

Corporate Details

ISIN(s):
ES0167733015
LEI:
95980063R15RDF29DK13
Country:
Spain
Address:
Sant Ferran 74, 08940 Cornellà de Llobregat
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics. The company discovers, develops, and plans to commercialize innovative, personalized medicines for diseases with high unmet medical needs. Utilizing its proprietary epigenetics platform, Oryzon focuses on two main therapeutic areas: oncology and central nervous system (CNS) disorders. The platform enables the identification and validation of biomarkers and therapeutic targets, translating them into advanced clinical programs.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Oryzon Genomics S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 00:00
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de A…
Spanish 44.3 KB
2025-05-26 08:04
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
Spanish 139.0 KB
2025-05-26 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
Spanish 139.0 KB
2025-05-12 07:52
Earnings Release
La sociedad remite información sobre los resultados del primer trimestre de 2025
Spanish 370.8 KB
2025-05-08 08:06
Regulatory News Service
ORYZON recibe una ayuda no reembolsable de 13,26 millones de € para su proyecto…
Spanish 250.1 KB
2025-04-29 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-04-25 13:52
Declaration of Voting Results & Voting Rights Announcements
Se comunica la inscripción en el Registro mercantil de la escritura de ampliaci…
Spanish 202.4 KB
2025-04-24 08:13
Share Issue/Capital Change
Resultado de la colocación acelerada
Spanish 178.7 KB
2025-04-23 18:34
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
Spanish 195.2 KB
2025-04-23 17:58
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
Spanish 195.2 KB
2025-02-28 14:54
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
Spanish 51.6 KB
2025-02-28 00:00
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
Spanish 55.0 KB
2025-02-27 19:03
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
Spanish 189.1 KB
2025-02-27 18:57
Governance Information
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
Spanish 437.0 KB
2025-02-27 00:00
Annual Report
Spanish 13.7 MB

Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT
VALIRX PLC Logo
Developing early-stage therapeutics & diagnostics for oncology and women's health.
United Kingdom VAL